pharmaphorum

SEPTEMBER 17, 2024

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with the launch of its new operating system for the wearable.The Breathing Disturbances function is part of watchOS 11, which makes its debut today alongside the release of the latest Apple Watch Series 10 which was revealed at the company's new product reveal earlier this month and is due to become available on 20th September.

Production 105

Production 105

Bio Pharma Dive

SEPTEMBER 17, 2024

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Development 312

Development Manufacturing Trials 312

Pharmaceutical Technology

SEPTEMBER 17, 2024

Drones are starting to play a vital role in the clinical supply chain across sub-Saharan Africa to reach more patients.

Clinical Supply Chain 246

Clinical Supply Chain Clinical Supply 246

Bio Pharma Dive

SEPTEMBER 17, 2024

The funding will support mid-stage testing of a drug the company believes to have the potential to treat a range of neurodegenerative conditions.

Drugs 306

Drugs 306

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharmaceutical Technology

SEPTEMBER 17, 2024

Poseida Therapeutics has received RMAT designation from the US FDA for its CAR-T cell therapy, P-BCMA-ALLO1.

241

241

Bio Pharma Dive

SEPTEMBER 17, 2024

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.

Trials 284

Trials Drugs 284

Bio Pharma Dive

SEPTEMBER 17, 2024

Backed by Bristol Myers Squibb, Ratio Therapeutics has a front row seat to the pharmaceutical industry’s pivot into the field of targeted radiation drugs.

Drugs 147

Drugs 147

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 17, 2024

Biology is opening up new frontiers in medicine. We are witnessing a revolution in healthcare, driven by advances in genetics, Omics, RNA and CRISPR gene-editing technology, to deliver precision and personalised medicine, said Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics. This holds the potential to cure genetic diseases that have plagued families for generations.

Genetic Disease 185

Genetic Disease Genetics Gene Editing Medicine 185

Pharmaceutical Technology

SEPTEMBER 17, 2024

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed sepsis.

147

147

Bio Pharma Dive

SEPTEMBER 17, 2024

The pharmacy benefit manager said its lawsuit is necessary to protect against misinformation about the industry, while the FTC promised to defend its research.

Pharmacy 130

Pharmacy Research 130

Advertisement

Clinical Supply

Pharmaceutical Technology

SEPTEMBER 17, 2024

BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.

Development 130

Development 130

Fierce Pharma

SEPTEMBER 17, 2024

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.

FDA Approval 129

FDA Approval Marketing 129

Pharmaceutical Technology

SEPTEMBER 17, 2024

The partnership will see AI-enabled screening used to address bioavailability issues with Equillium’s cytokine-targeting peptide.

Bioavailability 130

Bioavailability 130

Fierce Pharma

SEPTEMBER 17, 2024

With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its cust | With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its customers.

Marketing 121

Marketing 121

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharmaceutical Technology

SEPTEMBER 17, 2024

The company claims that the FTC’s July 2024 report is riddled with “false and misleading claims” about the PBM industry.

Drugs 130

Drugs 130

Pharma Times

SEPTEMBER 17, 2024

The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension

Research 121

Research Drugs 121

Pharmaceutical Technology

SEPTEMBER 17, 2024

Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.

130

130

BioPharma Reporter

SEPTEMBER 17, 2024

The FDA has granted Orphan Drug and Rare Pediatric Disease Designations to Somiteâs cell replacement therapy for the treatment of Duchenne muscular dystrophy.

Drugs 115

Drugs Development 115

Advertisement

Clinical Supply

Pharmaceutical Technology

SEPTEMBER 17, 2024

The SBTi has validated and approved India's Piramal Pharma’s near-term greenhouse gas (GHG) emission reduction targets.

130

130

Fierce Pharma

SEPTEMBER 17, 2024

Three months after a jury awarded $260 million to an Oregon woman who claimed | Three months after a jury awarded $260 million to an Oregon woman who claimed that her use of Johnson’s Baby Powder caused her to develop mesothelioma, a state judge has overturned the verdict and granted the company a new trial.

Trials 114

Trials Development 114

Pharmaceutical Technology

SEPTEMBER 17, 2024

Sanofi has commenced the shipping of BEYFORTUS to the US for healthcare providers and the Vaccines for Children programme.

Vaccine 130

Vaccine Vaccination 130

pharmaphorum

SEPTEMBER 17, 2024

Boehringer will file its idiopathic pulmonary fibrosis drug nerandolimast next year, a successor to its blockbuster Ofev, after a phase 3 win

Drugs 110

Drugs Trials 110

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Pharmaceutical Technology

SEPTEMBER 17, 2024

MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.

Licensing 130

Licensing Licensing Gene 130

pharmaphorum

SEPTEMBER 17, 2024

Tobacco giant PMI is selling pharma unit Vectura for a fraction of the £1.

109

109

Outsourcing Pharma

SEPTEMBER 17, 2024

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.

Marketing 107

Marketing Drugs 107

pharmaphorum

SEPTEMBER 17, 2024

Mitigating diagnostic errors in clinical trial participants: The role of drug safety/pharmacovigilance Mike.

Clinical Trials 108

Clinical Trials Clinical Trials Trials Drugs 108

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Outsourcing Pharma

SEPTEMBER 17, 2024

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

pharmaphorum

SEPTEMBER 17, 2024

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line treatment with EGFR inhibitors.The HERTHENA-Lung02 study in EGFR-mutated non-small cell lung cancer (NSCLC), involving patients with locally advanced or metastatic disease previously treated with EGFR drugs, revealed a significant improvement in progression-free survival (PFS) compared to a chemotherapy regimen.

Drugs 96

Drugs 96

Fierce Pharma

SEPTEMBER 17, 2024

Nearly a year after Coherus BioSciences’ on-body injector for Udenyca was rejected over external production issues, a third-party manufacturer has caused another spot of bother for the Ca | Thanks to “over-commitments and capacity constraints” facing the U.S.-based contractor in charge of final packaging for Coherus' Udenyca, the copycat cancer med will suffer a “temporary” supply interruption, the company said last week.

Contract Manufacturing 87

Contract Manufacturing Manufacturing Packaging Packaging 87

BioPharma Reporter

SEPTEMBER 17, 2024

The original concerns of the US regulatory agency over the manufacturing of Eli Lillyâs Ebglyss seem to have been resolved, as the FDA greenlit the antibody drug on Friday.

FDA Approval 82

FDA Approval Drugs Antibody Manufacturing 82

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials